Sequencing EGFR-Targeted Therapies in NSCLC: Clinical Practice and Pharmacist Perspectives

This discussion examines how FDA-approved therapies for EGFR-mutated non–small cell lung cancer (NSCLC) are being sequenced in real-world clinical practice. Panelists will explore how factors such as disease stage, mutation subtype, prior treatment exposure, and emerging resistance patterns influence therapeutic decision-making across lines of therapy. The evolving role of the pharmacist will be highlighted, particularly in supporting treatment selection through guideline interpretation, drug–drug interaction assessment, and coordination of care within the multidisciplinary team. In addition, the session will address key adverse events associated with EGFR tyrosine kinase inhibitors, bispecific antibodies, and antibody–drug conjugates, with an emphasis on monitoring, early identification, and management strategies. Together, these insights provide a practical framework for optimizing sequencing, improving tolerability, and maximizing outcomes for patients with EGFR-driven NSCLC.